compani
posit develop oncolog
cyramza data trulic uptak sigilon deal diabet
focal pt
cyramza os/pf data commerci oppi modest given
trulic gain share nvo ozemp share due
limit access/reimburs lly/bi invest behind jardianc
pay hf trial stop earli ink low-risk/high-reward deal
develop encapsul cell therapi type diabet asset preclin
carri revenu look use bd improv oncolog
pipelin reiter ep support dcf
posit develop diabet oncolog
announc posit develop diabet oncolog oncolog
data cyramza second-lin hepatocellular carcinoma view
cyramza commerci opportun modest given patient number
us incid afp-high competit immuno-
oncolog io agent note click need look extern
bolster oncolog growth diabet note recent trulic data show
brand continu gain share novo nordisk nvo rate victoza
market nvo ozemp share one quarter
launch limit access reimburs ozemp allow trulic
take share space beyond need deliv
rewind cv outcom data read-out addit partner
boehring ingelhiem bi privat invest behind jardianc market-
lead think heart failur pivot trial could stop late
earli addit announc deal sigilon therapeut
privat develop commerci asset type diabet
base encapsul cell therapi intrigu new technolog platform
chronic diseas view deal low-risk/high-reward given earli
stage develop carri revenu model reiter
buy pt ep support dcf risk includ
pricing/competit pressur especi diabet commerci execut
regulatori clinic ip alimta risk
low-risk sigilon deal add new platform diabet pipelin
announc global collabor sigilon develop encapsul
cell therapi treatment type diabet strateg deal
tr target
compani
lli early-stag diabet pipelin increas lli presenc specif pipelin
current lack view encapsul cell therapi new technolog think
potenti treat seriou diseas without need immunosuppress thu hold promis
address chronic condit type diabet sigilon disclos asset diabet
still earli pre-clin stage per sigilon websit carri revenu
collabor time howev view market favor despit rel low
preval ada estim us case new diagnos annual due lack
innov evalu pharma estim global market sale compound-annual-growth-rate
come insulin insulin analogu develop
commerci effect encapsul cell therapi peak sale could billion dollar global
view financi view deal low-risk/high-reward deal close
pay up-front sigilon yield in-process charg result dilut
ep expect impact non- ep respons
 cost ind submiss lower ep
street top-end lli new impli rang singalo also elig
receiv develop commerci mileston payment well singl
doubl digit tier royalti futur product sale singalo respons develop
cost investig new drug applic ind submiss respons
clinic develop commerci cost deal up-front cost total
estim potenti non-risk-adjust peak sale encapsul cell therapi product
potenti technolog platform may hold outsid view low-risk
high-reward deal
trulic continu gain share rewind critic
lli trulic continu gain share market latest monthli trx/nrx climb
vs nvo victoza trulic face rise competit nvo ozemp
semaglutid limit payer access thu far kept share think impact
ozemp trulic modest could signific onward conting
rewind data rise competit ozemp nvo oral semaglutid
put addit pressur deliv favor cv outcom benefit trulic cv
outcom studi rewind expect read-out base diabet market model
expect global market grow mid-teen compound-annual-growth-rate trulic
maintain share model trulic sale vs street
lli invest jardianc expect boost perform
 partner bi continu invest behind jardianc signific room
growth view despit market leader lly/bi conduct rang
clinic trial jardianc think street underappreci heart failur chronic kidney diseas
opportun total on-going industry-sponsor phase trial jardianc aim recruit
patient see exhibit bode well uptak among opinion leader kol patient
expect lly/bi heart failur pivot trial emperor-reduc emperor-preserv
show rapid signific benefit primari cv endpoint potenti data compel enough
result earli stop trial interim analysi lly/bi also plan initi jardianc
chronic kidney diseas ckd trial bullish ckd indic base result
empa-reg outcom studi jardianc show reduct risk kidney diseas onset/
progress click note model jardianc allianc revenu vs street
estim share shift older gener therapi jardianc equat
jardianc sale bi conting discount rebat put upward pressur
out-year estim class take share quickli anticip also remind
base partnership account allianc revenu record gross margin impli
upsid jardianc out-year sale could meaning posit impact lli margin
cyramza data modest posit face competit
cyramza achiev primari os secondari endpoint studi
evalu cyramza vs placebo patient high alpha-fetoprotein afp-high safeti
cyramza well-toler grade advers event hypertens
 hyponatremia low sodium expect share full data upcom oncolog
meet like june liver diseas confer aasld novemb
plan initi global regulatori file cyramza conting
page
compani
full clinic data expect cyramza commerci opportun modest
small address patient popul ii intens competit especi io agent accord
nation cancer institut nci us incid patient death
second-lin even smaller address patient popul evidenc fact
fda grant orphan drug design bristol-my squibb buy opdivo patient
alreadi treat bayer bayn-d rate nexavar sorafenib
standard-of-car year import note cyramza label expect
limit afp-high patient account half advanc patient
diminish address market competit front note nexavar standard-of-car
 bayer launch stivarga uptak impact black warn
relat hepatotox think key hurdl cyramza go opdivo
approv sept click base robust data
catalyst cyramza os read-out rang studi evalu cyramza chemo urotheli
carcinoma bladder cancer expect howev note five
io agent alreadi approv us bladder cancer mean commerci opportun
cyramza limit indic well model cyramza sale slightli
street
need extern asset improv oncolog posit
intrigu intern asset current portfolio pipelin howev note
click think need look bolster oncolog growth busi develop
consid oncolog must-win high growth area oncolog grow
compound-annual-growth-rate accord recent industri research need becom better
posit order sustain long-term franchis sale growth manag appear eager execut
 oncolog say call look mani mani opportun would
reason expect busi year busi develop oncolog lilli remind
click enter three small/early-stag deal oncolog continu think
lli bd-appetit strateg financi standpoint focus early-stag asset
support comment call ambit phase phase concept
earlier clinic asset main target lilli rel underrepres
lot go price point think attract ideal think
look tuck-in oncolog asset reason valuat could potenti provid one
commerci asset well sever intrigu asset early-to-mid stage pipelin right
asset becom avail think plenti dri powder mid-siz acquisit
cash short term secur balanc sheet net debt/ebitda ratio
think could pursu acquisit larg without requir signific sharehold
dilut assum like focus primarili opportun rang
page
compani
studi look function heart patient heart failur take empagliflozin
empagliflozin outcom trial patient chronic heart failur reduc eject fraction emperor-reduc recruit
empagliflozin outcom trial patient chronic heart failur preserv eject fraction emperor-preserv recruit
studi test empagliflozin patient chronic heart failur reduc eject fraction hfref
studi test empagliflozin patient chronic heart failur preserv eject fraction hfpef
diabet studi linagliptin empagliflozin children adolesc dinamo tm
initi
studi empagliflozin treatment chronic kidney diseas ckd
page
compani
rate well
includ amort intang asset
dilut sigilon deal
page
compani
exhibit estim strh vs consensu
page
compani
page
compani
 alzheim partner azn
page
compani
exhibit incom statement
sale
page
compani
exhibit consolid balanc sheet
equival
st borrow current portion lt debt
accumul comprehens loss
common stock treasuri
total liabil sharehold equiti
page
compani
exhibit statement
chang defer tax
net oper
restrict cash releas acquisit
dispos prop equip
addit asset
reduct invest
addit invest
net invest
purchas common stock
chang st borrow cpltd
addit long-term debt
reduct long-term debt
net financ
effect exchang rate
cash/equival begin period
cash/equival end period
page
compani
lilli lead research-bas biopharmaceut compani focus drug discoveri
clinic develop manufactur commerci pharmaceut product human
anim diseas gener sale yoy gener
us ex-u market human medicin busi includ core franchis
neurosci diabet women oncolog cardiovascular contribut
 total sale global leader diabet arena new product
trulic basaglar collabor asset jardianc tradjenta lli oncolog franchis
compris inhibitor verzenio abemaciclib alimta cyramza portrazza lartruvo
also place stake ground establish immunolog franchis
launch taltz olumi lli fourth leg emerg growth target pain market
three late-stag asset galcanezumab lasmiditan tanezumab enter one
best new product cycl year histori new product launch trulic jardianc
rate buy base attract low-teen earn growth mid-singl
digit volum driven sale growth commit expand oper margin tight
cost manag new product cycl unfold
model assum doubl diabet franchis level
jardianc basaglar trulic offset declin establish product
humalog humulin expect jardianc take materi share market older
gener therapi owe cardiovascular-benefit estim share shift
older gener therapi jardianc equat sale conting discount rebat
put upward pressur out-year estim also expect doubl
oncolog franchis base support verzenio alimta cyramza
portrazza lartruvo verzenio third-to-market inhibitor segment data
junip studi nsclc ad anoth leg growth alimta expect benefit combo use
keytruda first-lin non-smal cell lung cancer nsclc alimta alreadi substanti
presenc non-squam nsclc market model assum maintain us exclus
alimta
immunolog taltz olumi baricitinib expect contribut sale
continu progress olumi clinic commerci despit delay us
rheumatoid arthriti file think olumi long-term growth benefit expand asset
commerci reach much possibl geograph eu/japan label expans
atop dermat system lupu erythematosu psoriat arthriti taltz posit captur
mid-teen percentag psoriasi treat patient popul next five year lastli lli
emerg pain franchis repres fourth leg growth differenti late-stag asset
significantli derisk galcanezumab lasmiditan tanezumab galcanezumab robust efficaci
placebo-lik safeti posit take materi share cgrp market lasmiditan first-in-class
molecul offer cardiovascular safeti advantag acut migrain standard-
oper leverag margin expans central thesi compani contain fix
cost grow revenu base next five year lli streamlin oper
improv cost structur posit achiev opex goal sale
valuat risk
pt assum trade ep reflect premium current
forward group averag forward price-to-earnings multipl think premium group averag
multipl justifi given lli diversifi volume-driven sale growth mid-singl digit sale
compound-annual-growth-rate oper leverag oper margin goe price
target support discount cash flow dcf intrins valu per share
page
compani
risk thesi revolv around price commerci execut regulatori clinic risk
face upcom patent expir ciali alimta well recent
expir patent strattera competit pressur trulic semaglutid humalog
biosimilar insulin lispro expect off-set four launch verzenio
galcanezumab olumi baricitinib lasmiditan
compani mention note
compani buy john bori
bayer ag bayn-d rate
novo nordisk a/ nvo rate
john bori herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
